ClinicalTrials.gg
CompletedNCT00038506Updated Apr 8, 2015

Study Of Investigational Regimen Combining FDA Approved HIV Drugs In HIV Subjects Experiencing Early Virologic Failure

A Phase 4 interventional study of abacavir/lamivudine/zidovudine and tenofovir in HIV Infection, sponsored by ViiV Healthcare. Completed at 27 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-04-08.

Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
100
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 98 studies testing tenofovir in HIV Infections — 1 open to participants now, 3 under way, 1 of them phase 3. Tenofovir · HIV Infections.

Enrollment
46th of 94
100 · median 99
Started
2002
with 1 other
Phase 4
27 of 98
none open now
Registered
15th of 98
by date

Among the 98 studies testing tenofovir in HIV Infections, this one is the 46th largest by enrollment of the 94 interventional ones that give a count, is one of 2 that started in 2002, is one of 27 in phase 4, and was the 15th registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

1 of the 98 studies testing tenofovir in HIV Infections is open now. Recruiting first, the newest first:

About tenofovir

Tenofovir: first FDA approval 2001 (VIREAD), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 98 studies testing tenofovir in HIV Infections, or all of them as a file.
02

Study summary

This study is a 48-week study to evaluate the efficacy and safety of an investigational regimen combining FDA approved HIV drugs in antiretroviral-experienced subjects failing on their first highly active antiretroviral therapy regimen.

03

Conditions studied

  • HIV Infection

Browse trials for

Keywords

  • HIV-1 TRIZIVIR Tenofovir
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Currently on an initial HAART (highly active antiretroviral therapy) regimen of 3TC/ZDV or 3TC/d4T and a PI (protease inhibitor) -boosted or unboosted- or NNRTI (non-nucleoside reverse transcriptase inhibitor).
  • Plasma - 1 RNA was \<400 copies/ml on at least 2 documented occasions prior to viral rebound.
  • Have a plasma HIV - 1 RNA value >400 copies/ml and \<10,000 copies/ml on 2 documented successive occasions (including screen) separated by at least 2 weeks.
  • A less than or equal to 100.

Exclusion criteria

Exclusion Criteria:

  • Have not taken Abacavir (ZIAGEN or TRIZIVIR) or tenofovir (VIREAD) previously.
  • Have not had an AIDS defining illness within 30 days of screen.
  • Pregnant or breast-feeding.
  • Specified viral genotypes upon screening.
  • And other inclusion or exclusion criteria to be evaluated by the physician.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants

Interventions

  • Drugabacavir/lamivudine/zidovudine
  • Also known as: abacavir/lamivudine/zidovudine

06

What researchers measure

Primary outcomes

  1. HIV viral load response at 48 weeks as measured by proportion of subjects with undetectable viral load.

    Time frame: 48 weeks

Secondary outcomes

  1. Safety Viral load response at 24 weeks Change in T-cell count Resistance Health outcomes

    Time frame: 24 weeks

07

Study locations

27 sites
  • GSK Investigational Site
    Los Angeles, California 90027, United States
  • GSK Investigational Site
    San Rafael, California 94903, United States
  • GSK Investigational Site
    Fort Lauderdale, Florida 33145, United States
  • GSK Investigational Site
    Jacksonville, Florida 32206, United States
  • GSK Investigational Site
    Lake Worth, Florida 33463, United States
  • GSK Investigational Site
    Miami Beach, Florida 33139, United States
  • GSK Investigational Site
    Miami, Florida 33136, United States
  • GSK Investigational Site
    North Miami, Florida 33161, United States
  • GSK Investigational Site
    Orlando, Florida 32804, United States
  • GSK Investigational Site
    Tallahassee, Florida 32303, United States
  • GSK Investigational Site
    Atlanta, Georgia 30309, United States
  • GSK Investigational Site
    Decatur, Georgia 30033, United States
  • GSK Investigational Site
    Chicago, Illinois 60657, United States
  • GSK Investigational Site
    Maywood, Illinois 60153, United States
  • GSK Investigational Site
    Lafayette, Indiana 47904, United States
  • GSK Investigational Site
    Berkeley, Michigan 48072, United States
  • GSK Investigational Site
    Bronx, New York 10461, United States
  • GSK Investigational Site
    New York, New York 10014, United States
  • GSK Investigational Site
    Valhalla, New York 10595, United States
  • GSK Investigational Site
    Tulsa, Oklahoma 74114, United States
  • GSK Investigational Site
    Arlington, Texas 76015, United States
  • GSK Investigational Site
    Dallas, Texas 75208, United States
  • GSK Investigational Site
    Dallas, Texas 75216, United States
  • GSK Investigational Site
    Dallas, Texas 75246, United States
  • GSK Investigational Site
    Houston, Texas 77004, United States
  • GSK Investigational Site
    Seattle, Washington 98104, United States
  • GSK Investigational Site
    Green Bay, Wisconsin 54301, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2002, a primary completion of Aug 2004 and a completion of Aug 2004. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 31, 2002
First posted
Jun 3, 2002
Start
Mar 2002
Primary completionActual
Aug 2004
CompletionActual
Aug 2004
Last update
Apr 8, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 8, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00038506
Lead sponsor
ViiV Healthcare
First posted
Jun 3, 2002
Start date
Mar 2002
Primary completion
Aug 2004
Completion
Aug 2004
Last update
Apr 8, 2015

Study contacts

GSK Clinical Trials, MD
study director · GlaxoSmithKline
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tenofovir

Start the discussion